 | |
| Clinical data | |
|---|---|
| Other names | α-Ethylphenethylamine; α-Ethylphenylethylamine; Butanphenamine; B; AEPEA |
| Routes of administration | Oral |
| Drug class | Norepinephrine–dopamine releasing agent;Stimulant |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C10H15N |
| Molar mass | 149.237 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Phenylisobutylamine, also known asα-ethylphenethylamine (AEPEA) or asbutanphenamine (B), is astimulantdrug of thephenethylamine andamphetamine families.[1][2][3] It is a higherhomologue ofamphetamine, differing from amphetamine's molecular structure only by the substitution of themethyl group at thealpha position of theside chain with anethylgroup.
Phenylisobutylamine acts as anorepinephrine–dopamine releasing agent (NDRA) and has been found to producestimulant-like andreinforcing effects in animals.[1][2][3] It shows much lowerpotency and a greater preference forinduction of norepinephrine release compared todextroamphetamine.[1]
"Phenylisobutylamine" is in fact a chemical misnomer becauseisobutylamine itself contains a branched chain. The correct name after this style for this class of compound would be "phenylsecbutylamine".
A number of notablederivatives of phenylisobutylamine are known, including the following:
Additional derivatives with longer αchains also exist, for instancepentedrone,MBDP,pentylone,MDPV, andhexedrone, as well as others, likemexedrone.
Whereas MDMA is aserotonin–norepinephrine–dopamine releasing agent (SNDRA), MBDB appears to be a highlyselectiveserotonin–norepinephrine releasing agent (SNRA) and with significant preference for induction of serotonin release overnorepinephrine release.[4][5][6][7]
The phenylisobutylamine counterparts of psychedelic phenethylamines and amphetamines, for instance MBDB (the α-ethyl homologue ofMDMA) and Ariadne (the α-ethyl homologue ofDOM), show greatly reduced or abolished psychedelic effects in comparison.[8][5][9] This has also applied toα-ethyltryptamine (αΕΤ), which is non-hallucinogenic in contrast toα-methyltryptamine (αMT).[10][4] In the case of Ariadne specifically, it may be due to reducedefficacy in activating theserotonin5-HT2A receptor.[8]
